🔗 Share this article

Given that America undertakes historic revisions to its vaccination guidelines, an unexpected name appears somewhat surprisingly: Høeg, a US-based sports medicine doctor and epidemiologist who initially gained attention by expressing skepticism about COVID-19 shots during the global health crisis and has concentrated on possible deaths after COVID-19 immunization in her short tenure at the FDA.

Proposed Changes to Pediatric Immunization Schedule

Public health authorities had intended to announce sweeping changes to the pediatric immunization program earlier this month, aligning the US with the Danish vaccine program, according to reports – a significant shift that would put the US out of alignment with a large portion of the global community with insufficient data for improved outcomes. The planned update has been delayed until the coming year.

Rather than the top vaccines chief, Tracy Beth Høeg is scheduled to address the audience at the event. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the center this calendar year.

Consolidating Power at the Agency

This interim role might represent a strengthened alliance between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad consolidate power at the agency – and it points to a greater focus upon rolling back long-standing vaccines at the FDA.

Høeg has often pushed for halting certain childhood shot schedules in the US to become more similar to the Danish model, a country with comprehensive healthcare and a number of inhabitants about the population of the state of Wisconsin.

To date statements, she has persisted in emphasizing on immunizations – usually the purview of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Doubts Over Background

Høeg has little discernible track record in drug development, approval processes or management, which has been typical for previous directors of the biologics center. She has worked at the FDA as a key advisor to the agency head and CBER since earlier this year.

“She appears not to have the requisite experience” for running the pharmaceutical oversight division, stated Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in running a major agency. She lacks background in drug approvals.”

Previous directors of CBER would “be deeply familiar with regulatory frameworks and the science of pharmaceutical innovation”, noted Janet Woodcock. “Frankly, she doesn’t have the sort of resume that prior appointees who ran the center have had.”

The drug center has an immense portfolio at the FDA, Woodcock pointed out.

“Everybody just zeroes in on the innovative therapies, but the off-patent medication office approves a multitude of generic medications. There is also a biologic copycat branch, over-the-counter program and so forth, and all of those must be looked after,” Dr. Woodcock said. “The area you overlook, that’s the thing that I always told people is going to cause problems.”

There is also, a major management component to the job, which oversees in excess of 5,000 staff members. “It’s a huge leadership role, if you perform it correctly,” she concluded.

Official Statement and Controversial Policies

When asked about questions about Dr. Høeg's qualifications and whether this appointment indicates greater collaboration among regulatory chiefs on immunizations, a press secretary stated that the “questions rely on flawed assumptions”.

“This background is consistent with the duties of her position,” the official stated, pointing to the period Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the agency head's recently launched priority voucher program, a controversial rapid drug-approval program that allegedly concerned her preceding directors. “How are these medications being picked for this voucher program? Who makes the calls?” Howard asked. “There’s a lot of confidentiality occurring at the agency right now.”

Overall, he stated, “the Food and Drug Administration seems to be moving towards laxer regulations of all drugs, with the exception of immunizations.”

Public Track Record on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if problematic, history, some experts have noted. She published a research paper using non-validated volunteer-provided data to estimate the rate of myocarditis after Covid immunization. She advised the state of Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to imply Covid vaccines are riskier than they are.

Part of her “desired changes” for the new government included altering regulations for recently developed shots and discontinuing “non-essential” immunizations, she stated post-election on a online show. At the FDA, Dr. Høeg has allegedly floated the idea of preventing adolescent males from receiving Covid vaccines.

“She’s an thorough dogmatist who starts off with her preconceived notions and works backwards to accommodate the science in a highly deceptive, untruthful way,” Howard stated.

Gaining Influence and a “Revenge Tour”

Høeg joined other dissenters, {like|